NOVARTIS AG Raised to Buy by Morgan Stanley
Morgan Stanley’s analyst Mark Purcell has upgraded his rating from Neutral to Buy. The target price has been lifted and is now set at CHF 101 compared to CHF 93 before.
Leave a Comment
Morgan Stanley’s analyst Mark Purcell has upgraded his rating from Neutral to Buy. The target price has been lifted and is now set at CHF 101 compared to CHF 93 before.